Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. 1. U.S. stocks tumbled Tuesday on hotter-than-expected retail inflation data. The surprise uptick in the January consumer price index sent bond yields higher and the Dow , the S & P 500 and the Nasdaq all down more than 1% each. Frankly, we're not surprised to see the pullback in equities because the market has been up 14 out of the past 15 weeks. The new CPI data put market expectations around interest rate cuts more in line with the Federal Reserve's commentary. Good news for the Club: We have a large cash position. This dip if it were to continue could present another buying opportunity. However, we're staying patient for now. 2. Wall Street continued singing the praises of Palo Alto Networks . Jefferies analysts raised the cybersecurity name's price target to $450 per share from $350. Stifel analysts boosted theirs to $410 from $280. Research analysts at both firms cited strong channel checks ahead the cybersecurity leader's quarter earnings release next week. Jefferies said the biggest risk on Palo Alto right now is its 29% year-to-date gains, which far outpace the S & P 500's roughly 4% increase. The stock more than doubled in 2023. Like analysts overall, we think Palo Alto has a great setup for the year, given the surging demand for cybersecurity offerings. 3. Jefferies boosted Eli Lilly's price target to $853 per share from $815. The analysts are growing more confident in the safety profile of orforglipron, the company's GLP-1 weight loss/diabetes pill going through the drug trial process. That's critical to its commercial future because Pfizer discontinued one of its experimental GLP-1 pills due to toxicity issues last year. Alongside quarterly earnings, Eli Lilly said it plans to build supply of orforglipron ahead of approval because it sees such a strong opportunity. We're bullish on this because the company has a track record of making the right calls — both in terms of efficacy and safety. If Lilly shares weren't climbing higher in Tuesday's down market, we would consider buying more, given the solid fundamentals and serious growth prospects. The leading GLP-1s on the market — Lilly's Zepbound and Mounjaro, and Novo Nordisk 's Ozempic and Wegovy — are injectables (Jim Cramer's Charitable Trust is long PANW, LLY. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
News RelatedHere's why we would be considering buying more Eli Lilly shares if they were down Tuesday
News Related